| Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Co. is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Co.'s primary product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. This pathway is central to the regulation of calcium deposition and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels. We show 3 historical shares outstanding datapoints in our INZY shares outstanding history coverage, used to compute INZY market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INZY market cap history over the course of time is important for investors
interested in comparing INZY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INZY versus a peer is one thing; comparing
INZY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INZY can fluctuate over the course of history.
With this page we aim to empower investors researching INZY by allowing them to research the INZY market cap history.